N/A
Completed N=13
Intranasal CO2 for Allergic Rhinitis
Source: ClinicalTrials.gov NCT00618410 ↗Enrolled (actual)
13
Serious AEs
0.0%
Results posted
Jan 2014
Primary outcomePrimary: Change From Diluent Challenge Contralateral Secretion Weight at Antigen Challenge — 6; 19.6 milligrams
Summary
The purpose of this study is to better understand the way in which CO2 (carbon dioxide) affects the symptoms of allergic rhinitis or hayfever.
Our intent is to determine if CO2 has an effect on nasal challenge with antigen as a predictor of whether it will have a beneficial effect on the treatment of seasonal allergic rhinitis.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Diluent Challenge Contralateral Secretion Weight at Antigen Challenge |
6; 19.6 | — |
| SECONDARY Change From Diluent Challenge Ipsilateral Secretion Weight at Antigen Challenge |
9; 32.6 | — |
| SECONDARY Change From Diluent Challenge Ipsilateral Histamine Level at Antigen Challenge |
0; 2.04 | — |
| SECONDARY Change From Diluent Challenge Contralateral Histamine Level at Antigen Challenge |
0; 0 | — |
| SECONDARY Eosinophil Influx [Pre-allergen] |
0; 0 | — |
| SECONDARY Eosinophil Influx [Post-allergen] |
0; 0 | — |
Eligibility Criteria
Inclusion Criteria
- Males and females between 18 and 45 years of age.
- History of grass and/or ragweed allergic rhinitis.
- Positive skin test to grass and/or ragweed antigen.
- Positive response to screening nasal challenge.
Exclusion Criteria
- Physical signs or symptoms suggestive of renal, hepatic or cardiovascular disease.
- Pregnant or lactating women.
- Upper respiratory infection within 14 days of study start.
Data sourced from ClinicalTrials.gov (NCT00618410). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.